Acurx Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage clinical biopharmaceutical company headquartered in Staten Island, New York. The company is dedicated to developing a novel class of small molecule antibiotics designed to treat difficult-to-treat bacterial infections caused by priority pathogens. Acurx's proprietary approach utilizes a Gram-positive selective spectrum (GPSS®) targeting the DNA polymerase IIIC (pol IIIC) enzyme to inhibit bacterial DNA replication. This novel mechanism of action differentiates its pipeline from existing antibiotic therapies, offering microbiome-sparing activity and a favorable anti-recurrence bile-acid profile.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Preparing to advance lead antibiotic candidate ibezapolstat into international Phase 3 clinical trials for acute CDI, while seeking regulatory guidance to initiate clinical trials in the UK, Japan, and Canada.
Expected impact: Positions ibezapolstat as a potential first-line, standalone treatment for CDI with a unique microbiome-sparing and anti-recurrence profile.
Initiating a new open-label, 20-patient pilot clinical trial specifically targeting patients with recurrent C. difficile infection.
Expected impact: Aims to demonstrate ibezapolstat's clinical utility in preventing recurrence, potentially eliminating the need for secondary microbiome therapies.
Advancing preclinical candidate ACX-375C, a novel DNA polymerase IIIC inhibitor targeting MRSA, VRE, and Anthrax infections.
Expected impact: Expands the company's pipeline into systemic Gram-positive priority pathogens and bioterrorism threats.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High-resolution cryo-EM structural biology collaboration that mapped ibezapolstat bound to Gram-positive DNA pol IIIC at 3.2Å, providing a rational foundation for pipeline expansion.
Terms: Jointly funded public-private partnership.